SCHEMBL5677129

SCHEMBL5677129

CC1CC(=O)NN=C1c1ccc(C(=NN)c2ccc(O)c(C(=O)O)c2O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 13/20 0.46
▸ PDE3A Q14432 13/20 0.46
▸ TNNC1 P63316 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PDE4A P27815 2/20 0.40
▸ PDE4B Q07343 2/20 0.40
▸ PDE4C Q08493 2/20 0.40
▸ PDE4D Q08499 2/20 0.40
▸ GALR3 O60755 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5677114 1.00 PDE3B (0.46) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5679329 0.87 PDE3B (0.51) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5681207 0.83 SMN1; SMN2 (0.51) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5681194 0.83 SMN1; SMN2 (0.51) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5675191 0.79 PDE3B (0.64) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL6496001 0.76 PDE3B (0.65) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5679278 0.74 PDE3B (0.55) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5679287 0.74 PDE3B (0.55) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL5677120 0.74 PDE3B (0.53) PDE3BPDE3ATNNC1SMN1; SMN2MAPT
SCHEMBL4414285 0.73 PDE3B (0.64) PDE3BPDE3ATNNC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265871-B1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORP (FI) 2006-02-08 — — EP disclosed
US-6699868-B2 INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE ORION CORPORATION (FI) 2004-03-02 — — US disclosed
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure ORION CORPORATION (FI) 2003-08-21 — — US disclosed
EP-1265871-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2002-12-18 — — EP disclosed
WO-2001068611-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure FABP3, TNNI3, TNNT2 PDE3B 1154/4885PDE3A 667/4885TNNC1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback